Carrying a G6PC Variant? What the Research Really Says About Von Gierke Disease (GSD Type Ia)

Carrying a G6PC Variant? What the Research Really Says About Von Gierke Disease (GSD Type Ia)

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Von Gierke disease (glycogen storage disease type Ia) is an autosomal recessive condition. Research shows it appears only when a person inherits two broken copies of the G6PC gene. Being a single-copy carrier does not cause the disease. A national reference (OMIM #232200) and the 2014 ACMG practice guideline anchor these facts, and a genetic counselor can translate them into your family’s real numbers.

What you’ll learn

• What carrying one G6PC variant actually means for you and for future children.
• How the disease is managed today, from cornstarch diets to a gene therapy still in trials.
• How to tell a consumer carrier screen apart from diagnostic-grade clinical testing.
• What US and Canadian law does (and does not) protect after a genetic result.

How Von Gierke Disease Is Inherited: The G6PC Gene

Glycogen storage disease type Ia is caused by variants in the G6PC gene, also written G6PC1. This gene carries the instructions for glucose-6-phosphatase, an enzyme that lets the liver release stored sugar into the blood. When the enzyme does not work, the body cannot free glucose during fasting, so blood sugar drops dangerously low.

The gene sits on chromosome 17q21. A person has two copies of it, one from each parent. The disease is inherited in an autosomal recessive pattern, meaning both copies must carry a loss-of-function variant to cause the disorder.

Think of it like a backup generator with two switches. If even one switch still works, the lights stay on. Only when both switches are broken does the power fail. A carrier has one working switch, so they typically show no symptoms.

This is why parents who each carry one altered copy usually feel completely healthy. They pass the trait silently until two carriers have a child together.

The biochemistry behind the disease is worth understanding, because it explains every downstream symptom. Glucose-6-phosphatase catalyzes the final step of releasing glucose into the blood. It acts at the end of two pathways at once: glycogenolysis, the breakdown of stored glycogen, and gluconeogenesis, the making of new glucose. When the enzyme is missing, both taps that refill blood sugar are shut off during fasting.

The enzyme is expressed mainly in the liver, kidney, and intestine. That is why the liver and kidneys carry the heaviest long-term burden in this disease, a point the surveillance section revisits below. In untreated infants, the shutdown typically shows itself around three to four months of age. The early signs research most often reports are:

• An enlarged liver (hepatomegaly).
• Severe low blood sugar, sometimes with seizures.
• A buildup of lactic acid in the blood (lactic acidosis).
• High blood fats (hypertriglyceridemia) and high uric acid (hyperuricemia).

One more distinction matters when you read a report. Type Ia comes from the G6PC gene, which makes the enzyme itself. Type Ib comes from a different gene, SLC37A4, which moves sugar across a membrane. The two types are catalogued separately in reference databases, so check which one your result names.

If your carrier report or family history raises questions, a genetic counselor can map exactly which gene and variant you carry. You can find one through the National Society of Genetic Counselors.

Section recap: Type Ia results from two broken copies of the G6PC gene on chromosome 17q21. One working copy is enough to keep a carrier healthy.

Risk Magnitude: Turning “Carrier” Into Real Family Numbers

The condition is rare. Research reports the overall incidence of GSD type I at about 1 in 100,000 births. Type Ia accounts for roughly 80 percent of all GSD type I cases. So in plain terms, fewer than 1 baby out of every 100,000 is born with this disorder.

Carrier status is far more common than the disease itself, but a single copy still causes no illness. You do not have a “partial” or “mild” version of von Gierke disease from one variant. You simply carry it.

The math changes only when two carriers plan a child together. In that case, each pregnancy carries a fixed set of odds. Studies of autosomal recessive inheritance give the same pattern every time.

• About 25 out of 100 pregnancies (25%): the child inherits two variants and is affected.
• About 50 out of 100 (50%): the child is a healthy carrier, like each parent.
• About 25 out of 100 (25%): the child inherits no variant at all.

Unlike a risk-factor gene that only nudges the odds, two loss-of-function G6PC copies are effectively fully penetrant for the biochemical disorder. In everyday terms, if a child inherits both broken copies, the enzyme problem follows. That is why a confirmed two-carrier couple deserves careful counseling before the 25% figure feels abstract.

It helps to separate two different kinds of gene results here. Some variants only tilt the odds of a common disease, so a person with the variant may never develop it. Biallelic G6PC loss-of-function is not like that. When both copies fail, the enzyme step they control simply cannot happen, so the biochemical disorder follows. That is what “fully penetrant” means in plain terms.

These are population averages, not a prediction for one family. A genetic counselor or your primary care physician can confirm your partner’s status and give you the number that actually applies to you.

Section recap: The disease affects about 1 in 100,000 births. Two confirmed carriers face a 25% chance of an affected child per pregnancy, a risk worth reviewing with a counselor.

Testing Options: 23andMe Carrier Reports vs. Diagnostic Testing

Not all genetic tests answer the same question. A consumer carrier screen, such as one from 23andMe, checks a fixed, limited set of variants. It is designed to screen, not to diagnose, and it does not look at every possible change in the gene.

Diagnostic-grade testing works differently. Ordered through a clinician, it can include full G6PC sequencing plus deletion and duplication analysis. That work is done at a clinical laboratory such as Invitae, Color, GeneDx, or a hospital genetics lab. This looks across the whole gene, not a preset list.

The table below sums up the two paths side by side.

Feature	Consumer carrier screen (e.g. 23andMe)	Diagnostic-grade testing
Purpose	Screening only	Confirming a diagnosis
Variants covered	Fixed, limited set	Full G6PC sequencing + deletion/duplication
How you order it	Direct to consumer	Through a clinician
Where it runs	Consumer lab	Clinical lab (Invitae, Color, GeneDx, hospital)
A negative result	Reduces but does not rule out carrier status	More complete confirmation

Think of it like checking a book for typos. A consumer screen skims a few famous pages you already suspect. Diagnostic sequencing reads the entire book, cover to cover.

For a sick infant, doctors combine several clues. Diagnosis is established by identifying two pathogenic variants in the responsible gene, either G6PC1 for type Ia or SLC37A4 for type Ib. In practice this pairs clinical and biochemical findings with that molecular confirmation. Modern molecular testing has largely replaced the older reliance on liver biopsy and enzyme assays.

The NIH Genetic Testing Registry lists which clinical tests exist and which labs run them, which helps separate consumer screens from confirmatory testing. If a consumer result concerns you, ask your clinician or a genetic counselor about ordering a diagnostic-grade test through a certified lab. You can start at NSGC.org.

Section recap: Consumer screens test a limited variant list and only screen; diagnostic sequencing through a clinician reads the whole G6PC gene and confirms a result.

Interpreting Your Result: Diagnosis, Carrier, or VUS

A genetic report can feel like a foreign language, so learn its three key words. First, a consumer carrier report showing one G6PC variant usually means carrier status, not disease. It signals that you carry a single copy and are typically healthy.

Second is the “variant of uncertain significance,” or VUS. The ACMG and AMP variant-classification framework sorts findings into five tiers: pathogenic, likely pathogenic, uncertain, likely benign, and benign. A VUS is one the lab cannot yet call harmful or harmless, and it may be reclassified later as evidence grows.

These three results are easy to mix up, so here is the plain-language difference:

• Carrier: one G6PC variant on a consumer report; you are typically healthy and did not “get” the disease.
• VUS: a variant the lab cannot yet call harmful or harmless; not proof of a problem, and it may be reclassified later.
• Negative: no covered variant found; reassuring, but consumer screens read only selected variants, so it does not fully rule out carrier status.

Think of a VUS like a word you cannot find in the dictionary yet. It is not proof of a problem; it is a gap that future research may fill in either direction.

Third, a negative consumer result is reassuring but not final. Because these screens cover only selected variants, a negative reduces but does not fully rule out carrier status. Diagnostic sequencing is more complete.

The safe move for any positive, negative-but-worrying, or uncertain consumer result is the same. Confirm it with a clinical laboratory and review it with a board-certified genetic counselor before you act on it. A counselor at NSGC.org can explain exactly what your specific variant classification means.

Section recap: One variant on a consumer report usually means carrier status. A VUS is unclassified and may change, and any consumer result deserves clinical confirmation.

Management Standard: Cornstarch, Diet, and Lifelong Surveillance

For people who do have the disease, decades of research have shaped a clear standard of care. The 2014 ACMG practice guideline defines the cornerstone as keeping blood sugar normal through frequent feeds and uncooked cornstarch. Some patients also use continuous overnight feeds to avoid the long fasting gap of sleep.

Uncooked cornstarch works because the body digests it slowly. Picture a log on a fire instead of dry kindling. It releases glucose gradually over hours, smoothing out the severe fasting lows that define the disease.

Care does not stop at blood sugar. The guideline builds a lifelong plan around several fronts:

• Prevent low blood sugar: frequent feeds and uncooked cornstarch, with overnight feeds for some patients.
• Control secondary metabolic problems: lactic acidosis, high blood fats (hyperlipidemia), and high uric acid (hyperuricemia).
• Watch the liver: surveillance for hepatocellular adenomas, growths that can rarely turn into hepatocellular carcinoma.
• Watch the kidneys and body: monitoring for progressive kidney disease, plus growth and bone health.

Untreated infants often first appear around three to four months old with an enlarged liver, severe low blood sugar, and these metabolic disturbances. The kidney and liver focus traces back to where the missing enzyme normally works.

The evidence that careful care changes outcomes is substantial. A large European cohort study, the European Study on Glycogen Storage Disease Type I, followed 288 patients, including 231 with type Ia. Its median age at data collection was 10.4 years, with some patients well into adulthood. The study documented the full range of long-term issues, from liver adenomas and kidney disease to growth and puberty. It concluded that modern dietary management markedly improves survival and long-term outcome.

This is chronic, specialist-supervised care, not a cure. If you or a family member is affected, a metabolic specialist and your primary care physician should direct the plan. A genetic counselor at NSGC.org can support the family alongside them.

Section recap: Standard care is uncooked cornstarch and frequent feeds to prevent low blood sugar, plus lifelong surveillance of the liver and kidneys, all specialist-supervised.

Latest Treatment Landscape: DTX401 Gene Therapy (Investigational)

The newest frontier is a gene therapy called DTX401. It uses an adeno-associated virus serotype 8 (AAV8), a harmless delivery shell, to carry a working copy of the human G6PC gene into the liver. The goal is to restore some of the missing enzyme at its source.

This therapy did not appear out of nowhere. Research reviews describe DTX401 as an investigational AAV8 vector expressing human G6PC1, evaluated first in an earlier phase 1/2 trial in adults before moving to the pivotal study. That step-by-step path is normal for gene therapy, where early trials test safety before larger ones test benefit.

The pivotal study is a Phase 3 trial listed on ClinicalTrials.gov as NCT05139316, also called GlucoGene. It is a double-blind, randomized, placebo-controlled trial in patients aged 8 and older, splitting participants 1:1 between DTX401 and placebo. Its main measured outcome is the change in daily cornstarch intake from baseline to Week 48. The design also includes a blinded crossover at Week 48, so participants first assigned to placebo later receive DTX401.

The topline results, announced in 2024, met that primary endpoint. The numbers below compare the treated group with placebo at Week 48.

Week 48 measure	DTX401 group	Placebo group
Mean reduction in daily cornstarch	41.3%	10.3% (p<0.0001)
Reached at least a 30% reduction	68%	13%
Reached at least a 50% reduction	37%	4%

Longer-term data reported in 2025 were also encouraging. At Week 96, treated participants showed even greater cornstarch reductions while maintaining glucose control, with improved fasting tolerance. Across the follow-up, reports did not observe the AAV8 class effects of nerve-cluster toxicity, malignancy, or a blood-clotting complication.

Here is the honest, essential caveat. Regulatory status matters as much as the trial data, so it is worth stating plainly:

• US Food and Drug Administration: not approved; investigational as of 2026.
• Health Canada: not approved; investigational as of 2026.
• Open questions: durability, long-term safety, and access all remain unresolved.

As of 2026, DTX401 is investigational and is not approved by the US Food and Drug Administration or by Health Canada. Do not treat it as an available option. If a trial interests you, ask your metabolic team about eligibility and review ClinicalTrials.gov, and a genetic counselor at NSGC.org can help you weigh it.

Section recap: DTX401 gene therapy hit its Phase 3 endpoint in 2024 with durable Week 96 data in 2025, but it remains investigational and unapproved by the FDA and Health Canada as of 2026.

Family Implications: Cascade Testing and Reproductive Options

A genetic result rarely stops with one person. When someone is confirmed as a carrier or is affected, relatives may want to know their own status. This is called cascade testing: siblings and close family consider carrier testing, and a reproductive partner may pursue carrier screening.

Think of it like a phone tree. One confirmed result gives each branch of the family the chance to learn its own risk and plan ahead, rather than being surprised later.

For couples where both partners carry a variant, genetic counseling can lay out several reproductive paths without pushing any single choice. These commonly discussed options include:

• Informed natural conception.
• Prenatal diagnosis during pregnancy.
• Preimplantation genetic testing with IVF.
• Donor gametes (egg or sperm).

Each option has trade-offs that are deeply personal.

No article should make this decision for you. These are private choices best made with a board-certified genetic counselor who knows your specific variants and values. You can find one through NSGC.org, and your primary care physician can help coordinate referrals.

Section recap: A confirmed result lets relatives consider cascade testing, and counseling can outline reproductive options, all of which are personal decisions for you and a genetic counselor.

Psychosocial and Legal Context: GINA, Insurance, and Disclosure

Worry about how a result might be used is normal and worth addressing directly. In the United States, the Genetic Information Nondiscrimination Act (GINA, 2008) prohibits discrimination based on genetic information in health insurance and in employment. Its employment side is enforced by the EEOC and bars employers from requesting or using your genetic information in job decisions.

But GINA has a real gap, and you should know it before testing. The table below shows where its protection reaches and where it stops.

Area	Covered by US GINA?
Health insurance	Yes
Employment decisions	Yes (enforced by the EEOC)
Life insurance	No
Disability insurance	No
Long-term-care insurance	No

The employment rules also generally do not apply to employers with fewer than 15 employees, and the military is an exception. Some US states have added their own laws in lines GINA leaves uncovered.

Think of GINA like a fence around two yards, health insurance and employment, that leaves the life-insurance yard open. Knowing where the fence ends helps you decide the order in which you handle testing and any insurance applications.

Canada goes further. Its Genetic Non-Discrimination Act received Royal Assent on 4 May 2017. It bars anyone from requiring a genetic test or its results as a condition of a service or contract, including insurance. The Supreme Court of Canada upheld the law in 2020, and its protection reaches beyond health insurance and employment.

Beyond the law sits the emotional weight: deciding whether and how to tell siblings, and carrying uncertainty. Genetic counseling helps with both the decision and the disclosure conversation. A counselor at NSGC.org, together with your physician, can guide you through it.

Section recap: US GINA protects health insurance and employment but not life, disability, or long-term-care insurance; Canada’s 2017 law is broader, and a counselor can help with disclosure.

Frequently Asked Questions

Will I get the disease if my report shows one G6PC variant? Almost certainly not. Von Gierke disease requires two loss-of-function copies, and a single-copy carrier is typically healthy. Confirm any consumer result with a clinical lab and a genetic counselor before drawing conclusions.

Will my children inherit glycogen storage disease type Ia? Only if both you and your partner are carriers. In that case, each pregnancy carries about a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of neither. Carrier screening of your partner and genetic counseling give you your family’s real numbers.

Will this affect my health or life insurance? In the US, GINA protects health insurance and employment but not life, disability, or long-term-care insurance. Canada’s 2017 law is broader and reaches insurance and contracting more generally. Understanding this gap is part of the decision, and a genetic counselor can walk you through it.

Can my employer find out? Under GINA, US employers generally cannot request, require, or use your genetic information in employment decisions. The rule usually exempts employers with fewer than 15 employees and the military. If this worries you, discuss it with a genetic counselor before testing.

Should I get a second opinion or diagnostic test? Yes, confirmation is wise. A consumer screen tests only a limited variant set and can miss carrier status, so a clinician-ordered diagnostic test reads the whole gene. A board-certified genetic counselor at NSGC.org can arrange it and interpret the result.

Summary

Von Gierke disease (GSD type Ia) is an autosomal recessive condition caused by two broken copies of the G6PC gene. Carrying a single copy does not cause illness; the real family math appears only when two carriers plan a child, at a 25% affected-child risk per pregnancy. Consumer screens can flag carrier status but do not diagnose, so any result deserves clinical confirmation and counseling.

For those affected, the 2014 ACMG guideline defines uncooked cornstarch, careful diet, and lifelong surveillance as the standard of care, and modern management has markedly improved outcomes. A gene therapy, DTX401, showed positive Phase 3 results in 2024 and durable Week 96 data in 2025. Yet it remains investigational and unapproved by the FDA and Health Canada as of 2026. The steadiest next step is a conversation with a board-certified genetic counselor and your physician, who can turn these facts into a plan for you.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. MedlinePlus Genetics, National Library of Medicine / NIH. Glycogen storage disease type I. https://medlineplus.gov/genetics/condition/glycogen-storage-disease-type-i/
2. Bali DS, Chen YT, Austin S, Goldstein JL. Glycogen Storage Disease Type I. GeneReviews (NCBI Bookshelf, NBK1312), University of Washington / NIH. https://www.ncbi.nlm.nih.gov/books/NBK1312/
3. Online Mendelian Inheritance in Man (OMIM), Johns Hopkins University / NCBI. Glycogen Storage Disease Ia; GSD1A, MIM #232200. https://omim.org/entry/232200
4. Kishnani PS, Austin SL, Abdenur JE, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genetics in Medicine (2014). https://www.nature.com/articles/gim2014128
5. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and the Association for Molecular Pathology. Genetics in Medicine 17:405-424 (2015). https://www.acmg.net/docs/standards_guidelines_for_the_interpretation_of_sequence_variants.pdf
6. Weinstein DA, et al. Safety and Efficacy of DTX401, an AAV8-Mediated Liver-Directed Gene Therapy, in Adults With Glycogen Storage Disease Type Ia (GSDIa). Journal of Inherited Metabolic Disease 48(2):e70014 (2025). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893205/
7. ClinicalTrials.gov, U.S. National Library of Medicine / NIH. A Phase 3 Study to Evaluate the Efficacy and Safety of DTX401 in Patients With GSDIa (NCT05139316, GlucoGene). https://clinicaltrials.gov/study/NCT05139316
8. Ultragenyx Pharmaceutical Inc. Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for GSDIa (2024-05-30). https://www.globenewswire.com/news-release/2024/05/30/2891103/20739/en/Ultragenyx-Announces-Positive-Top-Line-Results-from-Phase-3-Study-of-DTX401-Gene-Therapy-for-Glycogen-Storage-Disease-Type-Ia-GSDIa.html
9. Ultragenyx Pharmaceutical Inc. Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for GSDIa (2025-09-08, ICIEM 2025). https://www.globenewswire.com/news-release/2025/09/08/3146441/20739/en/Ultragenyx-Announces-Positive-Longer-term-Data-from-Phase-3-Study-of-DTX401-AAV-Gene-Therapy-for-the-Treatment-of-Glycogen-Storage-Disease-Type-Ia-GSDIa.html
10. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GPA. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). European Journal of Pediatrics 161(Suppl 1):S20-S34 (2002). https://pubmed.ncbi.nlm.nih.gov/12373584/
11. NIH Genetic Testing Registry (GTR), NCBI / NLM. Glycogen storage disease due to glucose-6-phosphatase deficiency type IA (condition C2919796). https://www.ncbi.nlm.nih.gov/gtr/conditions/C2919796/
12. U.S. Equal Employment Opportunity Commission (EEOC). Genetic Information Discrimination (GINA, 2008), Title II. https://www.eeoc.gov/genetic-information-discrimination
13. National Human Genome Research Institute (NHGRI) / NIH. Genetic Discrimination and the Genetic Information Nondiscrimination Act (GINA). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
14. Parliament of Canada / Supreme Court of Canada. Genetic Non-Discrimination Act (S.C. 2017, c.3); Reference re Genetic Non-Discrimination Act, 2020 SCC 17. https://laws-lois.justice.gc.ca/eng/acts/G-2.5/
15. Kishnani PS, et al. Glycogen storage diseases. Nature Reviews Disease Primers 9:46 (2023). https://www.nature.com/articles/s41572-023-00456-z

---

Last updated: 2026-07-29

Author: greencafe editorial team. This article aggregates 15 sources from peer-reviewed medical literature and public health agencies (tier 1=9 / tier 2=4), including the NIH (MedlinePlus, GeneReviews, OMIM, the Genetic Testing Registry, and NHGRI), the U.S. EEOC, Canadian federal statute, ACMG guidelines, and PubMed-indexed publications.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Genetic Diseases category

🌐 日本語版: 糖原病1a型（フォン・ギールケ病）は遺伝する？キャリア判定と最新遺伝子治療